Alopecia

Latest News

April 5th 2024

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

March 22nd 2024

COVID-19 Impacts on Hair Loss, Pemphigus, Urticaria, and Rare Diseases

By Lauren Buchanan, MA, Managing Editor

March 18th 2024

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

By Cameron Santoro

March 12th 2024

What’s New in Hair Loss Therapies and Exosomes?

By Kaitlyn Bader, Senior Editor , Ronda Farah, MD

March 6th 2024

Pointers With Portela: Hair Loss Q&A

By Dustin Portela, DO

CME Content

Video

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Register now!

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

ByEmma Andrus, Associate Editor

March 5th 2024

The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

ByCameron Santoro

March 4th 2024

Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.

Alopecia

Latest News

CME Content

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

Trending on Dermatology Times

FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus

Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo

Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"

How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World

Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses